Skip to content
Open access

Intra-individual lipoprotein(a) variability and risk reclassification in patients with cardiovascular disease

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

The concept of lifelong Lp(a) stability is challenged and consideration of repeated Lp(a) measurements in selected patients with established cardiovascular disease is supported.

Abstract

Lipoprotein(a) (Lp(a)) is traditionally regarded as a genetically determined and stable cardiovascular risk factor, often assumed to require only a single lifetime measurement. However, emerging evidence suggests that intra-individual Lp(a) levels may fluctuate over time. In this study, we aim to investigate the magnitude and prevalence of intra-individual Lp(a) variability in patients with established cardiovascular disease (CVD). We analyzed longitudinal Lp(a) measurements from 1,570 CVD individuals(69.3% male)with baseline and follow-up testing between 2020 and 2025 at University Hospital Basel. Intra-individual Lp(a) variability was defined as an absolute change ≥25 nmol/L or a relative change ≥25%. Baseline Lp(a) levels were categorized as low (<75 nmol/L), intermediate (75–124 nmol/L), or high (≥125 nmol/L), and transitions between categories were assessed. Associations between Lp(a) variability with age, sex, BMI, lipids parameters, renal function, and follow-up duration were examined. Baseline and follow-up Lp(a) levels were strongly correlated (Spearman ρ = 0.92, p < 0.001), indicating overall population-level stability. Nevertheless, 15.4% of individuals exhibited an absolute Lp(a) change ≥25 nmol/L and 34.6% demonstrated a relative change ≥25%. Notably, 36% of individuals with intermediate baseline Lp(a) transitioned to a different risk category at follow-up. Lp(a) variability was more pronounced in females aged between 42 and 80 years than males of the same age. Lp(a) variability occurred significantly more often when the interval between measurements exceeded 3.5 years. In multivariable logistic regression models incorporating restricted cubic splines, changes in LDL-C were independently associated with Lp(a) variability (P <0.01, nonlinear P < 0.01). Intra-individual Lp(a) variability is substantial among CVD patients. Individuals with intermediate baseline Lp(a) levels are particularly prone to risk category reclassification. These findings challenge the concept of lifelong Lp(a) stability and support consideration of repeated Lp(a) measurements in selected patients.Graphical Summary

Read PDF

Similar papers

Open access Oct 2026

Serial lipoprotein(a) measurements reclassify cardiovascular risk and identify additional candidates for lipoprotein(a)-lowering therapy

Lipoprotein(a) (Lp(a)) has emerged as an important cardiovascular risk factor and is expected to become modifiable through several Lp(a)-lowering therapies in the near future. Current guidelines recommend measuring Lp(a) at least once in a lifetime, as levels are considered largely genetically determined. However...

P. Siegel, M. Gissler, M. Buechsel et al. · 0 citations
Open access Oct 2026

Dynamic and non-linear changes in lipoprotein(a) during acute coronary syndrome

Lp(a) shows a transient, non-linear increase during the acute phase of ACS associated with inflammatory response, and early post-ACS Lp(a) measurements may not reflect steady-state levels and should be interpreted cautiously.

S. Fujioka, K. Sakaguchi, H. Kusumoto et al. · 0 citations
Review Open access Oct 2026

Lipoprotein(a)-dependent cardiovascular risk in different populations: are thresholds the same?

The epidemiological, biological and methodological factors underlying variability in Lp(a) levels and their association with ASCVD across populations are explored, including the advantages and limitations of applying ancestry-specific Lp(a) risk thresholds.

B. Mansfield, F. Raal, Petri T. Kovanen et al. · 0 citations
Open access Oct 2026

Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability

Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...

M. Szarek, D. L. Bhatt, M. Miller et al. · 0 citations
Open access Oct 2026

Longitudinal patterns and determinants of lipoprotein(a) variability: a 15-year multi-center study

Lipoprotein(a) [Lp(a)] concentrations are mainly determined by genetic factors, yet evidence on their long-term variability and determinants remains limited, particularly among Asian populations. This study examined temporal changes in Lp(a) concentrations and identified clinical predictors of substantial...

Di Chen, C. Chang, Ming-Lung Tsai · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.